KOSDAQ-listed Syntekabio was strong early on the 12th. Expectations for earnings growth appear to have risen on news that Syntekabio will move into developing therapeutics based on its combined infrastructure of an "artificial intelligence (AI) platform–bio data center."
As of 9:18 a.m. that day, Syntekabio was trading at 5,470 won, up 1,255 won (29.77%) from the previous session. The share price spiked early in the session, hitting the upper limit (the top of the daily price band).
Syntekabio, an AI new-drug development company, said the previous day it will embark on next-generation therapeutic development based on its AI platform and bio data center. Its strategy is to preemptively implement the global pharmaceutical and biotech industry's evolution from single-target therapeutics to multi-target, personalized treatments.
Although it did not present specific new-drug development plans, it is interpreted that buying interest gathered on expectations for future earnings. The company said, "As the integrated build-out of an AI platform and a bio data center requires massive investment and time, Syntekabio, which has already completed and is operating this, has secured a high barrier to entry."